Information on this blog is being shared only for the purpose of creating legal awareness in public at large, especially in the field of Intellectual Property Right. As there may be possibility of error, omission or mistake in legal interpretation on the contents of this blog, it should not be treated as substitute for legal advise.
Tuesday, December 2, 2025
Bignet Solutions LLP Vs. Novex Communication Pvt. Ltd.
Ganraj Enterprises Vs. Landmark Crafts
Orient Cables (India) Limited Vs Office of the Regional Director
Ajay alias Vishal Veeru Devgan Vs The Artists Planet
Monday, December 1, 2025
Aristo Pharmaceutical Pvt. Ltd. Vs. Healing Pharma India Pvt. Ltd.
Brief Introductory Head Note — Summary of Case
This case decides an important issue in pharmaceutical trademark law: Can a company claim exclusive rights over a trademark that is created by shortening (clipping) a generic medicine name that is internationally recognised by the World Health Organisation? The High Court held that it cannot. Even when a trademark is formally registered, if it is substantially taken from a globally recognised International Non-Proprietary Name (INN)—which by nature belongs to the public—it cannot be monopolised. The Court also clarified that the mere fact that the rival trademark contains the full clipped portion of the Plaintiff’s trademark is not automatically infringement if the common part is generic or descriptive. The ruling heavily relied on earlier decisions of the Supreme Court and the Delhi High Court on descriptive marks and public domain names.
Factual Background
The Plaintiff, Aristo Pharmaceutical Private Limited, is a pharmaceutical company engaged in manufacturing pain-relief medicines. In 2003, the Plaintiff invented the brand name “ACECLO” by trimming the last five letters from the generic name Aceclofenac, an anti-inflammatory pain medicine recognised as a global INN by the World Health Organisation. Initially, the Plaintiff applied for registration with the prefix “ARISTO ACECLO”, which was granted in 2005. However, instead of using the full mark as registered, the Plaintiff marketed its products using only “ACECLO” prominently, making the prefix ARISTO insignificant on medicine packaging. Later in 2011, the Plaintiff also secured registration of the word mark “ACECLO” and its variant “ACECLO-MR.”
In 2024, the Plaintiff discovered that the Defendant Healing Pharma India Private Limited launched tablets under the name “ACECLOHEAL-MR,” “ACECLOHEAL-SP,” and “ACECLOHEAL-PLUS.” The Plaintiff issued a cease-and-desist notice in October 2024, claiming infringement and alleging that the Defendant’s mark unfairly used its registered trademark. The Defendant denied this claim, stating that “ACECLOHEAL” was an honest adoption combining first six letters of INN “Aceclofenac” + its own business name suffix “Heal”, and that no company can claim exclusive rights over an INN or any shortened (clipped) part of it under Section 13 of the Trade Marks Act, 1999.
Procedural History and Procedural Details
The Plaintiff filed Commercial IP Suit (L) No. 25932 of 2025 along with Interim Application (L) No. 26226 of 2025 before the Commercial Division of the High Court at Bombay seeking a temporary injunction to stop the Defendant from using ACECLOHEAL or ACECLO in any form. The matter was heard by Hon’ble Justice Sharmila U. Deshmukh, reserved on 14 November 2025, and finally pronounced on 25 November 2025. The Court analysed evidence including photographs, invoices, registrations, and the list of INNs produced by the Defendant.
Aristo Pharmaceutical Vs Healin…
Core Dispute (Issue for Determination)
The central legal question was:
“Does formal registration of a trademark guarantee exclusive rights if the trademark is heavily derived from a globally accepted generic INN medicinal name?”
Detailed Reasoning and Judicial Discussion by the Court (With Case Law and Citations Examined for Reasoning)
The Court began by observing that the Plaintiff’s original 2005 registration was “ARISTO ACECLO.” However, the Plaintiff itself admitted that it did not use the mark in the manner it was registered, but instead used only the clipped term ACECLO prominently, reducing the ARISTO prefix to insignificance. The Court held that this inconsistent usage undermines any claim of acquired distinctiveness from 2003 onward, because a company cannot claim reputation for a mark it never actually commercially used.
The core legal defence was based on Section 13 of the Trade Marks Act, 1999, which prohibits registration of:
commonly used or accepted names of a chemical compound, and
names declared by the World Health Organisation as international non-proprietary names (INN), or any name deceptively similar to such INN.
Section 13 also creates a legal assumption (deeming fiction) that any such mark registered in violation of this rule shall be considered wrongly entered or wrongly remaining on the register under Section 57, even if there is no direct challenge to its validity filed by a party.
The Defendant produced official WHO INN lists showing that “Aceclofenac” is an INN, meaning it is a public domain generic medicine name that no company can own exclusively. The Court rejected the Plaintiff’s interpretation that “deceptively similar” means only similar sounding words like “Aceclodenac” and not shortened words like “Aceclo.” The Court reasoned that:
A shortened or clipped mark that still carries the same meaning, association, or connotation of the original INN is also non-proprietary, descriptive, and falls within Section 13 prohibition.
To support this reasoning, the Court cited the Supreme Court decision in F. Hoffmann-La Roche & Co. Ltd. vs. Geoffrey Manners & Co. Pvt. Ltd., AIR 1970 SC 2062 (Neutral Citation not provided), holding that when part of a rival trademark is descriptive, the court must compare only the “distinct portions,” not the common descriptive part.
The Court also relied on a landmark principle from McCarthy on Trademarks and Unfair Competition, which states that abbreviated versions of a generic medicine name are still generic if they continue to carry the original meaning or association.
Further, the Court strongly applied the Delhi High Court’s ruling in Sun Pharmaceutical Laboratories Ltd. vs. Hetero Healthcare Ltd., 2022 SCC OnLine Del 2580 (marked before Supreme Court for principle reference), which held that when both parties adopt parts of INN name “Letrozole,” no exclusivity can be claimed for clipped portions.
Another crucial citation examined was Panacea Biotec Ltd. vs. Recon Ltd., 1996 PTC 16, where the Delhi High Court ruled that a mark derived from a generic medicine name is descriptive, cannot claim monopoly, and exclusive rights must be denied, because allowing ownership over generic pharmaceutical name is dangerous for public interest, competition, and free trade.
The Court then compared rival marks ACECLO vs. ACECLOHEAL, holding:
Both are clipped from “Aceclofenac” by deleting last five letters. The Defendant only added its own company identity word “Heal” to it. This is prima facie honest adoption. Because the shared part is INN-derived and descriptive, the Defendant cannot be restrained from using it.
On passing-off, the Court held that passing-off requires intentional misrepresentation, i.e., Defendant must attempt to sell its goods by pretending they are Plaintiff’s goods. The Court saw no such misrepresentation in packaging, font, style, or pricing. Both medicine packs visibly looked different. The Defendant also produced evidence showing several other companies also use clipped term “Aceclo,” proving it is widely used in the market. Pricing difference between rival products was also admitted.
Thus, the likelihood of public confusion is very low, because:
Medicine is Schedule-H drug (only on prescription),
Packaging is visually distinguishable,
Price is different,
And the common part of mark is descriptive and public domain.
Finally, the Court held:
When a trademark is taken substantially from an INN or its shortened part, registration does not grant exclusive monopoly, Section 13 overrides exclusivity claims, and infringement and passing-off relief must fail.
Decision (Operative Order)
The Interim Application seeking injunction was dismissed, holding that the Plaintiff has failed to establish a prima facie case of infringement or passing-off, because the trademark is derived from a global INN which is non-proprietary and public property.
Aristo Pharmaceutical Vs Healin…
Concluding Note
This ruling reinforces a balanced, fair, and public-interest-aligned approach in pharmaceutical trademark disputes. It highlights that trademark law, even when deployed in a commercial suit, must serve competition, consumer welfare, and prevent unfair monopolies—especially in medicines which directly impact the common man. It makes clear that while innovators can brand their medicines, they cannot own or block generic or internationally recognised medicine names, even in clipped form, if the shortened mark continues to reflect the same global INN association. The judgement is helpful not only for law students but also for manufacturers of generic medicines, chemists, and consumers fighting inflated monopoly claims.
Case Details (As Asked to be Reflected at Bottom)
Case Title: Aristo Pharmaceutical Private Limited Vs. Healing Pharma India Private Limited & Others
Order Date: 25 November 2025
Case Number: Commercial IP Suit (L) No. 25932 of 2025
Neutral Citation: 2025:BHC-OS:22177
Court: High Court of Judicature at Bombay, Commercial Division
Judge: Hon’ble Justice Sharmila U. Deshmukh
At the end, add this text:
Disclaimer: The information shared here is intended to serve the public interest by offering insights and perspectives. However, readers are advised to exercise their own discretion when interpreting and applying this information. The content herein is subjective and may contain errors in perception, interpretation, and presentation.
Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi
Suggested Journal Article Titles
Here are five suitable research paper titles for legal journal publication:
“Public Domain vs Private Monopoly: The ACECLO Trademark Battle and Section 13 Interpretation.”
“Clipped INN-Derived Pharmaceutical Trademarks: The Thin Line Between Branding and Descriptive Public Property.”
“Trademark Exclusivity in Medicines: Why Global INN Names Cannot Be Owned Even After Registration.”
“Pharmaceutical Trademark Infringement and Passing-Off Claims in INN-Derived Marks: A Consumer Welfare Perspective.”
“Section 13 of the Trade Marks Act, 1999 as a Shield Against Monopolization of Generic Drug Names: The ACECLOHEAL Dispute.”
The High Court of Judicature at Bombay, Commercial Division, in the case Aristo Pharmaceutical Private Limited vs. Healing Pharma India Private Limited & Others, by order dated 25 November 2025, in Commercial IP Suit (L) No. 25932 of 2025, decided by Hon’ble Justice Sharmila U. Deshmukh, has refused to grant interim injunction to the Plaintiff in a pharmaceutical trademark infringement and passing-off suit.
The dispute arose when the Plaintiff, holder of the registered trademark ACECLO, claimed that the Defendant’s adoption of ACECLOHEAL-MR, ACECLOHEAL-SP, and ACECLOHEAL-PLUS amounted to infringement and dishonest imitation. The Plaintiff argued that Section 28 of the Trade Marks Act, 1999 gave it exclusive rights over the mark and that no similarity challenge had been raised against its registration.
The Defendant countered that ACECLO is merely a clipped version of the WHO-recognised International Non-Proprietary Name “Aceclofenac,” and therefore falls under Section 13 of the Trade Marks Act, 1999, which prohibits monopoly or proprietary claims over INNs or any part thereof if the clipped form still carries the same meaning. The Defendant also argued that it had honestly added the suffix “Heal”—taken from its own company identity—to create a distinct composite mark.
The Court agreed with the Defendant, holding that a clipped or shortened version of an INN, which still points to the generic medicine, remains descriptive and public property (publici juris), and cannot be monopolized or protected exclusively, even if registered. The Court also noted that both marks were visually, phonetically and conceptually different in font, packaging and trade dress, and that the medicines were Schedule-H prescription drugs, further reducing the possibility of confusion. No evidence of intentional misrepresentation for unlawful gain (a core element of the tort of passing-off) was found.
Accordingly, the Interim Application seeking injunction was dismissed.=======
Capital Meters Ltd. Vs B.P. Electric
Brief Introductory Head Note Summary of case
This case revolves around a dispute over the use of the trade mark CAPITAL in the electrical goods market. Capital Meters Ltd., a company making electrical products like meters and switches since 1986, took legal action against B.P. Electric for using the same trade mark on fans. The court found that the defendant's use of the mark caused confusion among buyers, leading them to think the fans came from the plaintiff, and this hurt the plaintiff's business reputation built over years of sales worth crores of rupees.Capital-Meter-Vs-B-P-Electrical.pdf
Factual Background
The plaintiff company has been in the business of manufacturing and selling various electrical items such as electrical meters, transformers, switches, relays, alarms, and both industrial and domestic electric appliances under the trade mark CAPITAL starting from 1986. This trade mark CAPITAL is already registered for measuring apparatus and instruments, including energy meters, under Clause 9 of the Fourth Schedule of the Trade and Merchandise Marks Act, 1958. To expand protection, the plaintiff applied for registration in Classes 7, 9, and 11 at the Trade Mark Registry in New Delhi, with these applications advertised in the Trade Mark Journal and certificates expected soon. Through long, widespread, and exclusive use on electrical goods, the trade mark gained strong reputation and goodwill, with annual sales in crores, and it even forms a key part of the plaintiff's company name.Capital-Meter-Vs-B-P-Electrical.pdf
In January 1998, the plaintiff learned that the defendant started using the exact same trade mark CAPITAL for fans they made and sold across Delhi and other areas. The defendant sold these fans secretly without proper invoices, making the mark identical and confusingly similar in look and sound to the plaintiff's. Buyers ended up mistaking the defendant's fans for the plaintiff's products, allowing the defendant to profit from the plaintiff's hard-earned goodwill. The plaintiff's products faced damage to reputation due to the defendant's lower quality items sold under the same name.Capital-Meter-Vs-B-P-Electrical.pdf
Procedural Detail
The plaintiff sent a legal notice to the defendant asking them to stop using the trade mark, but the defendant refused in a written reply. This led the plaintiff to file a suit in court seeking a permanent injunction to stop the use, action for passing off and trade mark infringement, damages, and rendition of accounts. Summons were properly served on the defendant, but they did not appear or respond, so the court proceeded ex parte, meaning without the defendant's side. Evidence came through an affidavit by Dinesh Chand Gupta, the plaintiff's Director, who proved key documents like the company's Memorandum and Articles of Association, board resolutions authorizing the suit, the registration certificate for CAPITAL, pending applications, invoices and ads from Exhibits P-2 to P-21 showing long use, labels of both parties' marks, and the notice with reply.Capital-Meter-Vs-B-P-Electrical.pdf
Core Dispute
The main fight was whether the defendant infringed the plaintiff's registered trade mark CAPITAL and passed off their fans as the plaintiff's goods by using an identical mark on similar electrical products. The plaintiff argued this violated their statutory rights under the Trade and Merchandise Marks Act, 1958, and common law rights from reputation and goodwill. The defendant's secretive sales without invoices worsened the chance of buyer confusion, leading to loss for the plaintiff and unjust gains for the defendant.Capital-Meter-Vs-B-P-Electrical.pdf
Detailed Reasoning and Discussion by Court including on Judgement with Complete Citation Referred and Discussed for Reasoning
The court looked closely at the unrebutted evidence from the plaintiff, which clearly showed the defendant using CAPITAL on fans and passing them off as the plaintiff's. The labels were placed on record, proving the defendant's mark deceptively similar, sure to confuse ordinary buyers into thinking the fans came from the plaintiff. This use on similar goods like fans, which relate to electrical appliances, rode on the plaintiff's reputation from years of sales, causing real business loss while the defendant profited unfairly. The court noted the defendant copied the mark on purpose to trick buyers and cash in on the goodwill, as no defense was offered.Capital-Meter-Vs-B-P-Electrical.pdf
In its reasoning, the court relied on the Trade and Merchandise Marks Act, 1958, especially Clause 9 for registered measuring instruments, and principles of passing off from long exclusive use. No other cases were cited in the judgment, but the decision rested on proved facts: prior use since 1986, registration, pending wider applications, sales proof via Exhibits P-2 to P-21, and identical labels. The court held the plaintiff proved infringement and passing off fully, entitling them to relief. Thus, it granted permanent injunction per prayers (i) and (ii) of para 15 of the plaint, ordered delivery of all finished/unfinished goods, blocks, labels, boards, and literature with the offending mark for destruction per prayer (iii), and for accounts per prayer (iv), appointed Local Commissioner Mr. Yogesh Chaudhary (243, Lawyers Chambers, Delhi High Court) with Rs. 15,000 fee paid by plaintiff, for a preliminary decree on profits, allowing final decree later.Capital-Meter-Vs-B-P-Electrical.pdf
Decision
The suit succeeded fully with costs against the defendant. Permanent injunction issued restraining use of CAPITAL or any similar mark; delivery-up for destruction ordered; preliminary decree for profit accounts passed with commissioner appointed; decree sheet to be drawn up.Capital-Meter-Vs-B-P-Electrical.pdf
Concluding Note
This judgment strongly protects trade mark owners from copycats in related goods, stressing how identical marks on electrical items confuse buyers and damage goodwill. It shows courts act decisively ex parte when evidence is clear and unchallenged, upholding registration and reputation under the 1958 Act. A key lesson for businesses: long use builds rights even before full registration expands.Capital-Meter-Vs-B-P-Electrical.pdf
Case Title: Capital Meters Ltd. Vs B.P. Electric
Order date: October 12, 2001
Case Number: Suit No. 1413 of 1998
Neutral Citation: 2001:DHC:1155
Name of Court: Delhi High Court
Name of Hon'ble Judge: Sharda Aggarwal, J.Capital-Meter-Vs-B-P-Electrical.pdf
Disclaimer: The information shared here is intended to serve the public interest by offering insights and perspectives. However, readers are advised to exercise their own discretion when interpreting and applying this information. The content herein is subjective and may contain errors in perception, interpretation, and presentation.
Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi
Suggested 5 Suitable Titles for this Legal Analytical Article:
Guarding Goodwill: Trade Mark Protection in Electrical Goods Domain
From Meters to Fans: Decoding Infringement and Passing Off under 1958 Act
Ex Parte Triumph: Enforcing CAPITAL Mark against Deceptive Imitation
Reputation at Stake: Judicial Stand against Identical Marks in Allied Products
Injunction and Accounts: Lessons from CAPITAL Trade Mark Clash
- ============
Delhi High Court Grants Injunction to Capital Meters Ltd. in Trade Mark Clash with B.P. Electric
New Delhi, October 12, 2001: In Suit No. 1413 of 1998, the Delhi High Court, presided over by Hon'ble Justice Sharda Aggarwal, ruled in favor of Capital Meters Ltd. against B.P. Electric, issuing a permanent injunction for trade mark infringement and passing off of the mark CAPITAL.Capital-Meter-Vs-B-P-Electrical.pdf
Capital Meters Ltd., manufacturing electrical meters, switches, and appliances under CAPITAL since 1986, proved prior registration under Clause 9 of the Trade and Merchandise Marks Act, 1958, and substantial goodwill from crore-level sales. The court found B.P. Electric's use of the identical mark on fans deceptively similar, causing buyer confusion and business loss due to inferior quality products sold clandestinely without invoices.Capital-Meter-Vs-B-P-Electrical.pdf
Proceeding ex parte after the defendant's non-appearance, evidence via Director Dinesh Chand Gupta's affidavit confirmed long use through invoices, labels, and legal notice ignored by defendants. Justice Aggarwal decreed injunctions per plaint prayers (i)-(iii), ordered destruction of offending materials, and a preliminary decree for profit accounts via Local Commissioner Yogesh Chaudhary, with costs on defendant.Capital-Meter-Vs-B-P-Electrical.pdf
Disclaimer: This is for general information only and should not be construed as legal advice as it may contain human errors in perception and presentation: Advocate Ajay Amitabh Suman, IP Adjutor (Patent & Trademark Attorney), High Court of Delhi
===========
Rallis India Limited Vs Controller of Patent
Brief Introductory Head Note
The present case arises from an appeal before the High Court of Judicature at Madras challenging the order of rejection passed by the patent office. The main issue was whether a previously filed patent application could be treated as ‘prior art’ for judging the obviousness and novelty of the appellant’s formulation. The court examined the procedural fairness of the order, the correctness of relying on a provisional specification to set priority date, and whether the claimed emulsifiable concentrate (EC) formulation was actually disclosed in the provisional specification of the earlier patent. The judgment ultimately remanded the case for fresh decision by another officer.
Factual Background
The appellant, Rallis India Limited, filed Patent Application No. 4135/CHEN/2014 on 25 August 2014 for a “stable herbicidal composition containing pendimethalin and metribuzin in emulsifiable concentrate (EC) form” at the Indian Patent Office, Chennai. A request for examination was made on 27 September 2017. The patent office issued the First Examination Report on 22 July 2019, raising objections on lack of novelty and lack of inventive step under Section 2(1)(j) and Section 2(1)(ja) of the Patents Act, 1970, by citing prior documents AU760278B2, AU2012203353B2, and Proceedings of the Ninth Australian Weeds Conference, 1990.
Alongside, two opponents—Haryana Pesticide Manufacturers Association (HPMA) and Chimanbhai Chauhan—filed pre-grant oppositions under Section 25(1) of the Patents Act. HPMA’s opposition was filed on 10 September 2019, and pleadings were completed by 27 August 2021, with hearing concluded on 24 November 2021. The third respondent filed a separate pre-grant opposition a day before submissions were filed by HPMA; that second opposition concluded with hearing on 17 July 2023.
A key document used by all opponents was Patent No. IN 2243/MUM/2014, which also described pendimethalin and metribuzin compositions, and included dependent claim 17 referring to EC, ZC, OD, etc. This patent was initially filed provisionally on 9 July 2014 and later completed on 30 December 2014.
The appellant submitted amended specifications and two affidavits from experts, including by Vairamani Ramanathan, clarifying that the earlier provisional specification taught only SE formulation, not EC and even claimed that SE was superior to EC.
The controller rejected the claims on 5 March 2024.
Procedural Details
The appeal was filed under Section 117A(2) of the Patents Act, 1970. The appeal did not examine merits fully, but focused on legality of the rejection order. The court checked whether a ‘speaking order’ (reasoned order) was passed, and whether contentions, affidavits, and prior art reliance were examined in a fair and complete manner.
Core Dispute
The core dispute was whether the provisional specification of IN 2243/MUM/2014 actually disclosed an EC formulation so that its priority date could defeat the appellant's priority date of 25 August 2014. The appellant argued it does not, and hence cannot be treated as prior art for EC claims, because Section 11(2) mandates that the priority date of a claim can be taken from the provisional specification only if the claim is “fairly based on the disclosures” in it.
The opponents argued that the ranges overlap and compositions were already known, hence obvious. However, the impugned order never examined the appellant’s preliminary legal objection under Section 11(2) at all nor analysed all prior arts relied by opponents.
Reasoning and Detailed Discussion by Court
The court referred to Section 11(1), Section 11(2), Section 11(6), and Section 11A of the Patents Act, 1970 in full. It emphasised that priority date can flow from the provisional specification only if the claim is fairly based on it. When it examined the extracts from provisional specification, it found that the provisional specification of D3 related only to Suspo-Emulsion formulation and contained statements that SE formulations are better than EC, do not require solvents, contain no organic solvent and are water based. There was no disclosure of EC formulation at all. The later complete specification alone included claim 17 describing EC, OD, etc., but this came on 30 December 2014, which is after the appellant’s filing on 25 August 2014.
The court observed that though the appellant specifically raised this objection in the reply statement (Volume VI – pages 1026-1028) and written submissions (Volume VII – page 1186), the impugned order noticed that D3 is not a prior art under Section 25(1)(e) but failed to record any reasoning or finding on whether EC claim could derive priority from provisional specification. Hence, the order stood legally defective. The court also held that several other prior art documents used by opponents were not examined at all in the controller’s order. It was also noted that affidavits by experts were neither accepted nor rejected with reasons. This failure to deal with significant materials and issues rendered the order invalid in law.
Decision
The court set aside the rejection order dated 5 March 2024 and remanded the matter for fresh decision by another patent officer with direction to pass a speaking order within four months and without being influenced by the court’s prima facie remarks.
Concluding Note
This judgment stresses the importance of fairness, full reasoning, and proper legal foundation when rejecting a patent. It explains that if the earlier provisional specification does not disclose the exact subject matter claimed later (here, the EC formulation), then such later-added dependent claims cannot get priority back-dated to the provisional date. This protects the integrity of Section 11(2) of the Patents Act, which ensures that priority cannot be claimed for subject matter that was never disclosed at first filing.
Disclaimer: The information shared here is intended to serve the public interest by offering insights and perspectives. However, readers are advised to exercise their own discretion when interpreting and applying this information. The content herein is subjective and may contain errors in perception, interpretation, and presentation.
Case Title: Rallis India Limited Vs Controller of Patent
Case Number: C.M.A.(PT) 21 of 2024
Order Date: 20 November 2025
Neutral Citation: 2025:MHC:2659
Name of Court: High Court of Judicature at Madras, Chennai – Tamil Nadu
Hon’ble Judge: Justice Senthilkumar Ramamurthy
Written By: Advocate Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi
Five Suitable Suggested Titles for Publication
Simultaneous Priority Claims and the Test of ‘Fair Basis’ under Section 11(2) of the Patents Act, 1970
Rallis India Limited v. Controller of Patents: A Case Study on Procedural Fairness and Prior Art Reliance
The Doctrine of Fair Basis for Priority: Lessons from the Rallis India Patent Appeal
When Provisional Specification Falls Short: Understanding Section 11(2) through Rallis India Ltd.
Prior Art, Fair Basis, and the Imperative of a Reasoned Order: Insights from Rallis India Limited v. Controller of Patents
======
The case titled Rallis India Limited v. Controller of Patents, decided on 20 November 2025 in Case No. 4135/CHEN/2014, was delivered by Hon’ble Mr. Justice Senthilkumar Ramamoorthy of the High Court of Judicature at Madras. The appeal by Rallis India Limited challenged the patent controller’s rejection of its invention concerning a stable herbicidal composition of pendimethalin and metribuzin in Emulsifiable Concentrate (EC) form. The rejection order, originally issued on 5 March 2024, was examined by the High Court of Madras for legal correctness and procedural fairness.
The dispute largely centred on the controller’s reliance on an earlier filed patent (IN 2243/MUM/2014) as prior art with a priority date of 9 July 2014 (provisional specification). The appellant argued that the provisional filing of that earlier application only disclosed a Suspo-Emulsion (SE) formulation and never disclosed an EC formulation, and hence its priority could not be used against the appellant's EC claims as per Section 11(2) of the Patents Act, 1970. Although the controller acknowledged D3 was not prior art under Section 25(1)(e), the rejection order contained no clear reasoning or finding on the “fair basis” test for backdating priority for EC formulation. The appellant also pointed out that affidavits filed by technical experts, including by Vairamani Ramanathan and G.N. Kendapa, were not discussed or evaluated at all.
The High Court found that the rejection order failed to deal with important legal objections, did not evaluate expert affidavits, and did not consider several prior art documents submitted by opponents. The court held that such omissions rendered the order invalid in law as it was not a “speaking order” (reasoned order). Consequently, the court set aside the rejection and remanded the matter for fresh consideration by a different patent officer, directing that a detailed reasoned order be issued within four months without being influenced by the court's remarks.
This decision reinforces the importance of complete reasoning, fairness, and the requirement that priority dates for specific formulations must be fairly based on the provisional disclosures, failing which they cannot defeat later-filed inventions.
Disclaimer:This is for general information only and should not be construed as legal advice as it may contain human errors in perception and presentation: Advocate Ajay Amitabh Suman, IP Adjutor (Patent & Trademark Attorney), High Court of Delhi
======
Blog Archive
- March 2026 (38)
- February 2026 (44)
- January 2026 (80)
- December 2025 (108)
- November 2025 (62)
- October 2025 (44)
- September 2025 (75)
- August 2025 (103)
- July 2025 (95)
- June 2025 (93)
- May 2025 (118)
- April 2025 (91)
- March 2025 (148)
- February 2025 (116)
- January 2025 (58)
- October 2024 (8)
- September 2024 (34)
- August 2024 (68)
- July 2024 (39)
- June 2024 (57)
- May 2024 (49)
- April 2024 (6)
- March 2024 (44)
- February 2024 (39)
- January 2024 (21)
- December 2023 (29)
- November 2023 (23)
- October 2023 (27)
- September 2023 (33)
- August 2023 (29)
- July 2023 (29)
- June 2023 (2)
- May 2023 (1)
- April 2023 (5)
- March 2023 (6)
- February 2023 (1)
- November 2022 (17)
- October 2022 (11)
- September 2022 (30)
- August 2022 (46)
- July 2022 (36)
- June 2022 (26)
- October 2020 (1)
- September 2020 (1)
- April 2020 (1)
- March 2020 (1)
- February 2020 (2)
- December 2019 (1)
- September 2019 (3)
- August 2019 (2)
- July 2019 (1)
- June 2019 (2)
- April 2019 (3)
- March 2019 (2)
- February 2019 (2)
- January 2019 (2)
- December 2018 (3)
- November 2018 (1)
- October 2018 (2)
- September 2018 (2)
- August 2018 (8)
- July 2018 (2)
- June 2018 (1)
- May 2018 (41)
- April 2018 (7)
- March 2018 (3)
- February 2018 (4)
- January 2018 (2)
- December 2017 (6)
- November 2017 (4)
- September 2017 (5)
- August 2017 (6)
- July 2017 (1)
- June 2017 (1)
- May 2017 (10)
- April 2017 (16)
- November 2016 (3)
- October 2016 (24)
- March 2015 (2)
- January 2014 (1)
- December 2013 (4)
- October 2013 (2)
- September 2013 (7)
- August 2013 (27)
- May 2013 (7)
- September 2012 (31)
- December 2009 (3)
- September 2009 (1)
- March 2009 (3)
- January 2009 (2)
- December 2008 (1)
Featured Post
WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING
WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING IN ORDER TO PROVE THE TRADEMARK REGISTRA...
-
A Party is not allowed to argue a case, what is not pleaded. Introduction: This case revolves around a fundamental principle of civil proce...
-
Species patents following a Markush patent must demonstrate a distinct inventive step Introduction The AstraZeneca AB & Anr. Vs. Intas ...
My Blog List
-
शांति की कीमत - दरवाज़े पर एक दस्तक से, धड़कन बढ़ने लगती थी तब, सन्नाटा छा जाता वजूद पर, साँसें रुक-सी जाती थी तब। आँखें ढूँढती थी चेहरा, दिल किसी अनहोनी से डरता था, ...6 days ago
-
IPL:Spice In, Nationality Out - I was sitting in my office. It was a hot afternoon. The fan was running slowly and making strange sounds like an old typewriter. Files were lying on my d...10 months ago
-
-
My other Blogging Links
- Ajay Amitabh Suman's Poem and Stories
- Facebook-My Judgments
- Katha Kavita
- Lawyers Club India Articles
- My Indian Kanoon Judgments
- Linkedin Articles
- Speaking Tree
- You Tube-Legal Discussion
- बेनाम कोहड़ा बाजारी -Facebook
- बेनाम कोहड़ा बाजारी -वर्ड प्रेस
- बेनाम कोहड़ा बाजारी-दैनिक जागरण
- बेनाम कोहड़ा बाजारी-नवभारत टाइम्स
- बेनाम कोहड़ा बाजारी-ब्लॉग स्पॉट
- बेनाम कोहड़ा बाजारी-स्पीकिंग ट्री